EGFR and non-small cell lung carcinoma: Even though EGFR-targeted therapy has become the standard treatment in advanced EGFR-positive NSCLC, most patients eventually develop acquired resistance to first-generation EGFR-TKIs after 12–24 months of treatment (2–4).